No label defined (Q31024)
Jump to navigation
Jump to search
No description defined
- Prostate cancer in transgender women: A propensity score-matched analysis of disease severity and survival.
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
No description defined |
|
Statements
Despite the rise in gender-affirming care, our understanding of prostate cancer (PCa) in transgender women (TGW) remains in its infancy. (English)
BACKGROUND (English)
© 2024 American Cancer Society. (English)
2024
Health disparities and lack of PCa awareness and screening are possible barriers to providing quality care for this population. (English)
BACKGROUND (English)
© 2024 American Cancer Society. (English)
2024
In addition, the implication of hormonal manipulation for the aggressiveness of PCa in TGW is yet to be determined. (English)
BACKGROUND (English)
© 2024 American Cancer Society. (English)
2024
Here, this study sought to compare oncological characteristics and survival outcomes between transgender and cisgender (CG) patients with PCa via two national data sets. (English)
BACKGROUND (English)
© 2024 American Cancer Society. (English)
2024
The Veterans Affairs Informatics and Computing Infrastructure database (1999-2020) and the Surveillance, Epidemiology, and End Results-Medicare database (2010-2017) were reviewed. (English)
METHODS (English)
© 2024 American Cancer Society. (English)
2024
Demographic and clinical details were analyzed. (English)
METHODS (English)
© 2024 American Cancer Society. (English)
2024
Logistic regression analysis was performed on propensity score-matched groups to identify predictors of high-risk disease and metastasis in patients with PCa. (English)
METHODS (English)
© 2024 American Cancer Society. (English)
2024
Groups were matched 5:1 (CG:TGW) on the basis of age, race, year of diagnosis, and Charlson Comorbidity Index score. (English)
METHODS (English)
© 2024 American Cancer Society. (English)
2024
Primary outcomes included metastatic presentation, high-risk localized disease, overall survival (OS), and prostate cancer-specific mortality (PCSM). (English)
METHODS (English)
© 2024 American Cancer Society. (English)
2024
A total of 1194 patients were included (199 TGW; 995 CG). (English)
RESULTS (English)
© 2024 American Cancer Society. (English)
2024
Associations between transgender identity and metastatic presentation (odds ratio [OR], 0.38; p = .2), high-risk localized disease (OR, 1.19; p = .50), or PCSM (hazard ratio [HR], 0.65; p = .3) were not detected. (English)
RESULTS (English)
© 2024 American Cancer Society. (English)
2024
Transgender identity was associated with improved OS (HR, 0.67; p = .014). (English)
RESULTS (English)
© 2024 American Cancer Society. (English)
2024
PCa-specific outcomes seem comparable between TGW and CG men, although the study was underpowered to detect modest differences. (English)
CONCLUSIONS (English)
© 2024 American Cancer Society. (English)
2024
Further investigation into the incidence and outcomes of PCa in TGW is warranted. (English)
CONCLUSIONS (English)
© 2024 American Cancer Society. (English)
2024
Margaret (English)
Meagher (English)
M
Isabella (English)
Dolendo (English)
I
Christina (English)
Jamieson (English)
C
Farnoosh (English)
Nik-Ahd (English)
F
Stephen (English)
Freedland (English)
S
Jennifer (English)
Anger (English)
J
Amirali (English)
Salmasi (English)
A
25 October 2024
25 October 2024